Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANIA: Switching from ritonavir-boosted protease inhibitor + tenofovir disoproxil fumarate/emtricitabine to raltegravir + nevirapine + lamivudine in HIV patients with renal impairment
2013-001637-40Phase 2Terminated
- Sponsor
- MSD
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltegravir, nevirapine and lamivudine in human immunodeficiency virus infection (HIV), sponsored by MSD. Primary endpoint: Change in renal function (eGFR-MDRD) at Week 48. Started Jan 2014; status: terminated.
02
Drugs
raltegravirnevirapinelamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-001637-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001637-40.